Johnson & Johnson to invest $500m to end HIV and tuberculosis

This article was originally published here

Johnson & Johnson (J&J) will use the investment to advance research and development and delivery programmes to eliminate both diseases by 2030. The company will appoint a team

The post Johnson & Johnson to invest $500m to end HIV and tuberculosis appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply